By Joseph Adebanjo, M.S. Organic Chemistry | PMP | PMI-ACP
Biotech companies spend billions optimizing their biology.
The target. The molecule. The mechanism of action. The clinical outcome.
What gets far less attention is what happens after the reaction. The solvents used to run it. The disposable plasticware generated by it. The carbon footprint is embedded in every step of the synthesis process.
This is a chemistry problem. And in an industry that regularly talks about improving human health, it is one worth taking seriously.
How Big Is the Problem
Pharmaceutical manufacturing is one of the most solvent-intensive industries on the planet. A 2015 analysis published in the American Chemical Society’s journal Green Chemistry found that the pharmaceutical sector produces significantly more waste per kilogram of product than most other chemical industries, with solvent waste accounting for the largest share of that total.
To put it in concrete terms: for every kilogram of active pharmaceutical ingredient produced, the industry generates an estimated 25 to 100 kilograms of waste. The majority of that waste is solvent.
In early-stage drug discovery and synthesis, tracking the numbers is harder, but the pattern remains the same. Organic solvents like dichloromethane, dimethylformamide, and tetrahydrofuran are workhorses of synthetic chemistry. They are also toxic, difficult to recycle at the lab scale, and energy-intensive to dispose of properly.
The biology in a biotech pipeline may be groundbreaking. The chemistry supporting it is often not green.
What Biocompatible Solvents Actually Are
The term biocompatible solvent is used loosely in industry, but in the context of green chemistry it refers to solvents that meet two criteria. They must perform adequately in synthesis or processing applications, and they must present a significantly lower toxicological and environmental profile than the conventional solvents they replace.
Several categories are worth knowing:
Water is the most biocompatible solvent available. Aqueous reaction conditions are underutilized in synthetic chemistry because many organic substrates are poorly water-soluble. However, advances in micellar catalysis and water-compatible ligand design, areas directly connected to inorganic and coordination chemistry, are expanding what is possible in water-based systems.
Ethanol and Ethyl Acetate Both are derived from renewable feedstocks and are classified as preferred solvents in the GSK Solvent Selection Guide, one of the most widely used green chemistry frameworks in pharmaceutical development. Neither is perfect, but both represent meaningful improvements over chlorinated solvents in most applications.
2-Methyltetrahydrofuran (2-MeTHF) Derived from agricultural waste, 2-MeTHF is increasingly used as a direct replacement for tetrahydrofuran in many synthesis steps. It is easier to recover and recycle, has a higher boiling point that improves handling safety, and is biodegradable.
Cyrene is one of the more promising newer entries. Cyrene is a bio-derived dipolar aprotic solvent that can substitute for dimethylformamide and N-methyl-2-pyrrolidone in certain applications. Both of those conventional solvents carry significant toxicological concerns. Cyrene does not.
Supercritical Carbon Dioxide Used primarily in extraction and some specialized synthesis contexts, supercritical CO2 leaves no solvent residue and can be recycled within a closed system. The capital cost of the required equipment has historically limited adoption, but this is changing as the technology matures.
The Carbon Footprint of Drug Synthesis
Solvent waste is the most visible part of the environmental footprint of drug synthesis but it is not the only part.
Energy consumption in synthesis is significant. Reactions that require low temperatures, high pressures, or extended run times carry substantial energy costs. Catalyst design, particularly in transition-metal catalysis, where inorganic chemistry plays a central role, directly affects the efficiency and energy intensity of a synthesis route.
A well-designed catalyst can reduce the number of steps in a synthesis, lower the temperatures required, and improve yield, all of which reduce the overall carbon footprint of producing a given molecule. This is not a peripheral concern. For companies with net zero commitments, the carbon embedded in their synthesis processes is part of their reporting obligations.
Atom economy, a core principle of green chemistry introduced by Barry Trost in 1991, asks what percentage of the atoms in the starting materials actually end up in the final product. A synthesis route with poor atom economy generates more waste by definition, regardless of which solvents are used. Designing for high atom economy from the start is one of the most impactful ways a synthetic chemist can reduce the environmental footprint of a process.
Where Inorganic Chemistry Fits
Much of the conversation around green chemistry in biotech focuses on organic synthesis. But inorganic and coordination chemistry sit at the center of several of the most promising solutions.
Transition metal catalysts enable reactions that would otherwise require harsher conditions or more steps. Designing catalysts that are active under mild aqueous conditions, can be recovered and reused, or replace rarer, more toxic metals with earth-abundant alternatives, are all active areas of research with direct green chemistry implications.
Metal-organic frameworks are being explored as solvent-free platforms for chemical synthesis and separation processes. Inorganic membranes offer energy-efficient alternatives to distillation-based solvent recovery. Bioinorganic approaches to catalysis, drawing on the efficiency of metalloenzymes, point toward synthesis strategies that generate significantly less waste than conventional routes.
These are not distant possibilities. They are areas where chemistry research is actively changing what is feasible in pharmaceutical and materials manufacturing today.
What Biotech Companies Should Be Asking
If you are building or running an R&D pipeline, the green chemistry questions worth asking are practical ones.
Which solvents in your current synthesis workflows appear on restricted substance lists or carry the highest environmental and health hazard ratings? The GSK Solvent Selection Guide and the CHEM21 Solvent Selection Guide are both publicly available starting points.
Where in your synthesis route is waste generated at the highest volume? That is usually where green chemistry interventions deliver the most impact.
Is your catalyst design optimized for recoverability and reuse, or is it designed purely for yield?
Are your suppliers and contract research organizations measuring and reporting their solvent waste and carbon intensity? As environmental disclosure requirements expand, this will become a procurement consideration, not just an ethical one.
The Bigger Picture
The pharmaceutical and biotech industries exist to improve human health. The environmental footprint of how drugs are made is part of that mission, not separate from it.
Green chemistry is not a constraint on innovation. It is a design discipline. The chemists who understand both the science of synthesis and the environmental implications of their choices are the ones who will lead R&D teams as sustainability becomes a core operating requirement rather than a voluntary commitment.
The biology in your pipeline may be extraordinary. Make sure the chemistry supporting it is too.
About the Author: Joseph Adebanjo, PhD Candidate in Inorganic Chemistry | M.S. Organic Chemistry | PMP | PMI-ACP | Focused on the intersection of advanced chemistry research and project leadership in pharmaceutical and materials R&D.
